Novartis plots $700M biotech plant

Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. More than 300 people are expected to work there when it's complete in 2012.

It's Novartis' second big investment in Singapore manufacturing. The company just opened a new $180 million tabletting plant there today; it's expected to employ some 160 workers. Singapore was featured twice on our annual list of the top five regions attracting biotech business.

- check out the report from Channel News Asia

Related Articles:
Novartis injects $816.5M in vaccine plant. Report
Singapore to spend $8B on biotech R&D. Report
GSK opens $13M drug discovery lab in Singapore. Report
Singapore to spend $8B on biotech R&D. Report
GSK blueprints $190M vaccine plant for Singapore. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.